Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Rabe_Kyle_ENV_1000x714-transform

Kyle Rabe

Partner

Washington +1 202 662 5736

  • About
  • Representative Matters
  • Credentials
  • About

    Kyle Rabe represents clients in mergers and acquisitions, joint ventures, and other corporate transactions.

    He regularly advises clients in the life sciences industry in connection with significant M&A transactions, including acquisitions of public companies. He also represents clients in a variety of other industries, including sports, technology, and consumer products.

    Kyle also serves as co-chair of Covington’s multidisciplinary Digital Health Initiative.

    Kyle is a member of the Bar of New York and the Bar of the District of Columbia.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • UCB in various acquisitions and divestitures, including its:
      • $1.9 billion acquisition of Zogenix (NASDAQ: ZGNX);
      • $2.1 billion acquisition of Ra Pharmaceuticals (NASDAQ:RARX);
      • sale of Kremers Urban Pharmaceuticals to Lannett;
      • acquisition of Engage Therapeutics; and
      • acquisition of midazolam nasal spray from Proximagen.
    • Johnson & Johnson in various acquisitions and divestitures, including its:
      • acquisition of OrthoSpin;
      • acquisition of the JointPoint navigation software business;
      • acquisition of the CUPTIMIZE™ Hip-Spine Analysis business;
      • acquisition of Olive Medical;
      • acquisition of 3D printing technologies from Tissue Regeneration Systems;
      • sale of Prodisc; and
      • sale of RoC Skincare.
    • SK Innovation in its $13 billion joint venture with Ford Motor Company to manufacture electric vehicle batteries.
    • Merck in its $425 million acquisition of OncoImmune.
    • AbbVie in its $5.8 billion acquisition of Stemcentrx.

    • Allergan in its:
      • $2.1 billion acquisition of Kythera Biopharmaceuticals (NASDAQ: KYTH);
      • acquisition of Bonti;
      • acquisition of Chase Pharmaceuticals;
      • acquisition of ForSight VISION5; and
      • acquisition of Akarna Therapeutics.
    • AstraZeneca in its up to $4.3 billion acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance.
    • Salix Pharmaceuticals in its $2.6 billion acquisition of Santarus (NASDAQ: SNTS).
    • King Pharmaceuticals (NYSE: KG) in its $3.6 billion merger with Pfizer.
    • Aristocrat Leisure Limited in its $1.28 billion acquisition of Video Gaming Technologies.

    Areas of Expertise

  • Credentials
    Education
    • University of Virginia School of Law, J.D., 2009
    • London School of Economics, M.Sc., 2004
    • Georgetown University, B.A., 2003
    Bar Admissions
    • District of Columbia
    • New York
    Accolades
    • New York Super Lawyers, Mergers & Acquisitions "Rising Star" (2012-2021)

    Areas of Expertise

News and Insights

Events